Johannes Sam

2.7k total citations
26 papers, 487 citations indexed

About

Johannes Sam is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Immunology. According to data from OpenAlex, Johannes Sam has authored 26 papers receiving a total of 487 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 16 papers in Radiology, Nuclear Medicine and Imaging and 9 papers in Immunology. Recurrent topics in Johannes Sam's work include Monoclonal and Polyclonal Antibodies Research (15 papers), CAR-T cell therapy research (14 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Johannes Sam is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (15 papers), CAR-T cell therapy research (14 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Johannes Sam collaborates with scholars based in Switzerland, Germany and United States. Johannes Sam's co-authors include Christian Klein, Marina Bacac, Pablo Umaña, Roger J. Packer, Andy Gillespie, Diane E. Cole, Richard L. Heideman, Gregory H. Reaman, Lawrence J. Ettinger and Frank M. Balis and has published in prestigious journals such as Nano Letters, Blood and PLoS ONE.

In The Last Decade

Johannes Sam

23 papers receiving 474 citations

Peers

Johannes Sam
Thomas J. Fountaine United States
Rosalinda Castaneda United States
Takumi Sugimoto Japan
Sidhartha Tavri United States
Klaus Laimer Austria
Mario Otto United States
Yvonne Rubner Germany
Kezheng Wang China
Michael Armour United States
Thomas J. Fountaine United States
Johannes Sam
Citations per year, relative to Johannes Sam Johannes Sam (= 1×) peers Thomas J. Fountaine

Countries citing papers authored by Johannes Sam

Since Specialization
Citations

This map shows the geographic impact of Johannes Sam's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Johannes Sam with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Johannes Sam more than expected).

Fields of papers citing papers by Johannes Sam

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Johannes Sam. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Johannes Sam. The network helps show where Johannes Sam may publish in the future.

Co-authorship network of co-authors of Johannes Sam

This figure shows the co-authorship network connecting the top 25 collaborators of Johannes Sam. A scholar is included among the top collaborators of Johannes Sam based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Johannes Sam. Johannes Sam is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gottschlich, Adrian, Johannes Sam, Lisa Rohrbacher, et al.. (2024). CSF1R Targeting T Cell Engaging Bispecific Antibodies Enable Safe and Efficient Immunotherapies in Acute Myeloid Leukemia. Blood. 144(Supplement 1). 918–918.
2.
Kollert, Florian, Jason Neale, Nicolas Frances, et al.. (2024). AB1034 CHARACTERIZATION OF RO7507062, A CD19-TARGETING T-CELL BISPECIFIC ANTIBODY (CD19TCB), AND DESIGN OF A PHASE 1 TRIAL IN SYSTEMIC LUPUS ERYTHEMATOSUS. Annals of the Rheumatic Diseases. 83. 1837–1838.
3.
Hänel, Gerulf, Koorosh Korfi, Sylvia Herter, et al.. (2023). Fine Tuning Bispecific Activity in CLL: Harmonizing a CD19/20-T Cell Bispecific with a CD28 or 4-1BBL Costimulatory Bispecific. Blood. 142(Supplement 1). 2058–2058. 1 indexed citations
4.
Karlsen, Tine V., Marek Wagner, Olav Tenstad, et al.. (2021). Pharmacokinetics and Pharmacodynamics of T-Cell Bispecifics in the Tumour Interstitial Fluid. Pharmaceutics. 13(12). 2105–2105. 5 indexed citations
5.
Cremasco, Floriana, Elena Menietti, Johannes Sam, et al.. (2021). Cross-linking of T cell to B cell lymphoma by the T cell bispecific antibody CD20-TCB induces IFNγ/CXCL10-dependent peripheral T cell recruitment in humanized murine model. PLoS ONE. 16(1). e0241091–e0241091. 24 indexed citations
6.
Haegel, Hélène, Anneliese Schneider, Anna Maria Giusti, et al.. (2021). Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies. Journal for ImmunoTherapy of Cancer. 9(7). e002582–e002582. 27 indexed citations
7.
Sam, Johannes, Sara Colombetti, Tanja Fauti, et al.. (2020). Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity. Frontiers in Oncology. 10. 575737–575737. 38 indexed citations
8.
Cremasco, Floriana, Elena Menietti, Johannes Sam, et al.. (2020). L2 In vivo live imaging of human T/B cell lymphoma cross-linking mediated by bispecific CD20-TCB antibody. A1.2–A1. 1 indexed citations
9.
Herter, Sylvia, Johannes Sam, Claudia Ferrara, et al.. (2020). RG6076 (CD19-4-1BBL): CD19-Targeted 4-1BB Ligand Combination with Glofitamab As an Off-the-Shelf, Enhanced T-Cell Redirection Therapy for B-Cell Malignancies. Blood. 136(Supplement 1). 40–40. 8 indexed citations
10.
11.
Sam, Johannes, Christina Claus, Claudia Ferrara, et al.. (2018). Abstract 5621: FAP-4-1BBL: A novel versatile tumor-stroma targeted 4-1BB agonist for combination immunotherapy with checkpoint inhibitors, T-cell bispecific antibodies, and ADCC-mediating antibodies. Cancer Research. 78(13_Supplement). 5621–5621. 1 indexed citations
12.
Claus, Christina, Claudia Ferrara, Sabine M. Lang, et al.. (2017). Abstract 3634: A novel tumor-targeted 4-1BB agonist and its combination with T-cell bispecific antibodies: an off-the-shelf cancer immunotherapy alternative to CAR T-cells. Cancer Research. 77(13_Supplement). 3634–3634. 4 indexed citations
13.
Lehmann, Steffi, Johannes Sam, Sara Colombetti, et al.. (2016). In Vivo Fluorescence Imaging of the Activity of CEA TCB, a Novel T-Cell Bispecific Antibody, Reveals Highly Specific Tumor Targeting and Fast Induction of T-Cell–Mediated Tumor Killing. Clinical Cancer Research. 22(17). 4417–4427. 53 indexed citations
14.
Scheuer, Werner, Markus Thomas, P Hanke, et al.. (2016). Anti-tumoral, anti-angiogenic and anti-metastatic efficacy of a tetravalent bispecific antibody (TAvi6) targeting VEGF-A and angiopoietin-2. mAbs. 8(3). 562–573. 19 indexed citations
15.
Bacac, Marina, Pablo Umaña, Sylvia Herter, et al.. (2016). CD20 Tcb (RG6026), a Novel "2:1" T Cell Bispecific Antibody for the Treatment of B Cell Malignancies. Blood. 128(22). 1836–1836. 21 indexed citations
16.
Bacac, Marina, Tanja Fauti, Sara Colombetti, et al.. (2015). Abstract 2481: CEA TCB, a novel T-cell bispecific antibody with potent in vitro and in vivo antitumor activity against solid tumors. Cancer Research. 75(15_Supplement). 2481–2481. 1 indexed citations
17.
Heideman, Richard L., Diane E. Cole, Frank M. Balis, et al.. (1989). Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: evidence for dose-dependent plasma clearance of thiotepa.. PubMed. 49(3). 736–41. 111 indexed citations
18.
Blair, Phyllis B., et al.. (1987). Suppression of natural killer cell activity in young and old mice. Mechanisms of Ageing and Development. 40(1). 57–70. 7 indexed citations
19.
Blair, Phyllis B., et al.. (1983). Inhibitor Cells in Spleens of Mice With Low Natural Killer Activity<xref ref-type="fn" rid="FN2">2</xref><xref ref-type="fn" rid="FN3">3</xref>. JNCI Journal of the National Cancer Institute. 71(3). 571–7. 6 indexed citations
20.
Sam, Johannes. (1974). Accumulation and washout of glycerol in isolated rabbit atria. Journal of Molecular and Cellular Cardiology. 6(4). 373–381. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Thomas J. Fountaine Breakdown of academic impact, for papers by Rosalinda Castaneda Breakdown of academic impact, for papers by Takumi Sugimoto Breakdown of academic impact, for papers by Sidhartha Tavri Breakdown of academic impact, for papers by Klaus Laimer Breakdown of academic impact, for papers by Mario Otto Breakdown of academic impact, for papers by Yvonne Rubner Breakdown of academic impact, for papers by Kezheng Wang Breakdown of academic impact, for papers by Michael Armour
Rankless by CCL
2026